

Press release

Relations between IMA and Dr. Gianluca Vacchi

With reference to the interest generated by the active presence of Dr. Gianluca Vacchi on social media and the series of considerations that have appeared in the press over the last few days.

In line with its policy of transparent and ethical communication, as expected for a listed company, being cited on various occasions, IMA would like to give its shareholders and customers the correct information.

This in order to avoid misinformation on the life of the firm, which is exclusively focused on growth and on increasing the competitiveness of the Group as part of the global market, while respecting the history of a company that has strong local roots in Italy.

In this overall context, and for the purposes explained above, without wanting to interfere in the private decisions of those who may be related directly or indirectly to IMA S.p.A., we consider it worthwhile to specify the following:

- Dr. Gianluca Vacchi is a shareholder of IMA S.p.A. and a member of the Company's Board of Directors, as declared by him on several occasions. Dr. Vacchi does not have any powers and is not directly involved in the company's management.
- Dr. Gianluca Vacchi has for many years been an independent entrepreneur outside of IMA, without actively participating in the running of this company as he has always been satisfied with its overall performance and management. Again, as he has declared on various occasions.
- As for the the company's history, IMA was not founded by Gianluca Vacchi's father, as he has stated to contradict information that was not correct. IMA's origin was linked, more than half a century ago, to the will of the Vacchi family to invest the income earned from other activities in a number of innovative projects presented to them by inventors and designers who were very creative and technologically-minded. This meeting between the openminded vision of entrepreneurs and a strong technological base gave IMA the ability to grow on a solid foundation of research and innovation.

Established in 1961, IMA is world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals, cosmetics, food, tea and coffee. The Group has more than 5,000 employees, more than 2,600 of whom overseas, and can count on 38 production plants in Italy, Germany, France, Switzerland, Spain, the United Kingdom, the United States, India, Malaysia and China. IMA has an extensive sales network comprising 29 branches which provide sales and service in Italy, France, Switzerland, the United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, the United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and East European countries and over 50 agencies covering a total of about 80 countries. IMA S.p.A. has been listed on the Milan Stock Exchange since 1995 and in 2001 joined the STAR segment. The following manufacturing companies are part of the IMA Group: Benhil GmbH, Co.ma.di.s. S.p.A., Corazza S.p.A., Delta Systems & Automation Inc., Erca S.A., Erca-Formseal Ibérica S.A., Fillshape S.r.l., Gasti Verpackungsmaschinen GmbH, Gima S.p.A., Gima TT S.p.A., G.S. Coating Technologies S.r.l., Hamba Filltec GmbH & Co. KG, Hamba Verwaltungsgesellschaft mbH, Hassia Packaging Pvt. Ltd., Hassia Verpackungsmaschinen GmbH, Ilapak International SA, Ilapak Italia S.p.A., Ilapak (Langfang) Packaging Machinery Co. Ltd., IMA Life North America Inc., IMA Life (Beijing) Pharmaceutical Systems Co. Ltd., IMA North America Inc., IMA-PG India Pvt. Ltd., Komax Systems LCF SA, Komax Systems Malaysia Sdn. Bhd., Komax Systems Rockford Inc., PharmaSiena Service S.r.l., Revisioni Industriali S.r.l., Shanghai Tianyan Pharmaceutical Machinery Co. Ltd., Swiftpack Automation Ltd., Teknoweb Converting S.r.l., Telerobot S.p.A.

For further information:

Andrea Baldani - Investor Relator - tel. +39 051 783111 - e-mail: baldania@ima.it Maria Antonia Mantovani - Press Office - tel. +39 051 783283 - e-mail: antonia.mantovani@ima.it www.ima.it (Investor Relations section)